Amedisys, Inc. (NASDAQ:AMED – Get Free Report) has been assigned a consensus rating of “Hold” from the thirteen brokerages that are currently covering the company, MarketBeat.com reports. Ten investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $109.67.
A number of analysts recently weighed in on the stock. Cantor Fitzgerald increased their price target on shares of Amedisys from $100.00 to $101.00 and gave the stock a “neutral” rating in a research note on Thursday, September 14th. StockNews.com assumed coverage on Amedisys in a research report on Sunday, October 15th. They issued a “buy” rating on the stock. TD Cowen upped their price objective on Amedisys from $84.00 to $101.00 and gave the company a “market perform” rating in a research note on Monday, July 31st. Benchmark downgraded Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, June 27th. Finally, Barclays upped their price target on Amedisys from $88.00 to $101.00 in a research note on Tuesday, June 27th.
View Our Latest Stock Report on AMED
Institutional Trading of Amedisys
Amedisys Stock Down 0.2 %
AMED opened at $92.55 on Tuesday. Amedisys has a one year low of $69.36 and a one year high of $106.56. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.92 and a current ratio of 0.92. The stock has a market capitalization of $3.02 billion, a P/E ratio of 1,322.33, a price-to-earnings-growth ratio of 2.50 and a beta of 0.98. The business’s 50-day simple moving average is $93.22 and its 200-day simple moving average is $87.74.
Amedisys (NASDAQ:AMED – Get Free Report) last released its quarterly earnings results on Wednesday, July 26th. The health services provider reported $1.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.28. The firm had revenue of $552.97 million for the quarter, compared to the consensus estimate of $568.18 million. Amedisys had a return on equity of 14.00% and a net margin of 0.10%. The firm’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter last year, the business posted $1.47 EPS. Analysts anticipate that Amedisys will post 4.48 EPS for the current year.
About Amedisys
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Further Reading
- Five stocks we like better than Amedisys
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 High Dividend Stocks To Beat Treasury Yields
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- United Airlines Shares Fall Despite Solid Quarter
- Investing In Automotive Stocks
- Housing Starts Up, Homebuilders Down as Mortgage Rates Soar
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.
